Cost Is the Quiet Barrier to Adempas Adherence — Here's How to Address It

You prescribe Adempas (Riociguat) because it works. For patients with inoperable or persistent CTEPH, it's the only FDA-approved medication. For PAH patients, it offers a unique mechanism of action through sGC stimulation. The clinical evidence is clear.

But here's what the clinical trials don't capture: the moment your patient sees the price. At approximately $14,400 to $14,500 per month — roughly $173,000 per year — Adempas ranks among the most expensive oral medications in the country. And that price tag creates a real, measurable barrier to adherence.

Studies consistently show that out-of-pocket costs are one of the strongest predictors of medication non-adherence, especially for specialty drugs. When patients face high copays, coinsurance, or the specialty tier "sticker shock," they may delay filling prescriptions, skip doses, or abandon treatment entirely — often without telling you.

This guide equips you and your staff with actionable knowledge about every savings program available for Adempas in 2026, so you can integrate cost conversations into your clinical workflow.

What Your Patients Are Actually Paying

Before diving into solutions, it helps to understand the cost landscape your patients face:

Commercially Insured Patients

• Adempas is typically placed on the specialty tier (Tier 4 or 5) of most formularies
• Copays or coinsurance range from $100-$500/month to 20-33% of the drug cost, depending on the plan
• Annual deductibles must often be met before coverage kicks in, which can mean $2,000-$8,000 out of pocket at the start of the year
• Some plans use copay accumulators that prevent manufacturer assistance from counting toward the deductible or out-of-pocket maximum

Medicare Part D Patients

• The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs (fully effective since 2025) significantly helps Medicare patients on Adempas
• However, patients still face coinsurance during the initial coverage and coverage gap phases
• Manufacturer copay cards are not available to Medicare patients (Anti-Kickback Statute restriction)
• Medicare Part D Extra Help (Low-Income Subsidy) further reduces costs for qualifying patients

Uninsured Patients

• Full list price: $14,400-$14,500/month
• Without assistance, treatment is functionally inaccessible
• Patient assistance programs (detailed below) are the primary path to affordability

Medicaid Patients

• Medicaid typically covers Adempas with minimal patient cost-sharing
• Prior authorization is generally required
• Coverage varies by state Medicaid program

Manufacturer Savings Programs

Aim Co-Pay Assistance Program (Commercially Insured)

This is the most impactful program for the majority of your commercially insured patients.

• Benefit: Reduces copay or coinsurance to as low as $0
• Eligibility: Patients with commercial (private) insurance that requires a copay or coinsurance for Adempas
• Exclusions: Medicare, Medicaid, TRICARE, and other government insurance programs
• Duration: 12-month enrollment, renewable annually
• Annual cap: Per-patient annual maximum — contact program for current limits
• Enrollment: Call 855-423-3672 or visit adempas-us.com

Clinical workflow tip: Have your office staff initiate Aim enrollment at the same time as prior authorization. This prevents the common scenario where PA approval comes through but the patient balks at the copay before the assistance is in place.

Aim Patient Support Program (Broader Support)

Beyond copay assistance, the Aim program provides:

• Insurance navigation — helping patients understand their coverage and appeal denials
• Prior authorization support — assistance with PA submissions and appeals
• Specialty pharmacy coordination — connecting patients with REMS-certified pharmacies
• Nurse educator support — patient education on medication management

The Aim program is essentially a concierge service for Adempas access. Encourage every patient to call 855-423-3672 — regardless of insurance status.

Patient Assistance Programs (PAPs)

Bayer US Patient Assistance Foundation

For uninsured patients, this is the most direct path to free medication.

• Benefit: Provides Adempas at no cost
• Eligibility: Uninsured patients; income requirements apply
• Application: Through the Aim program (855-423-3672). Requires prescriber attestation, income verification, and proof of uninsured status
• Renewal: Must reapply annually

PAN Foundation (Patient Access Network)

An independent nonprofit that helps cover out-of-pocket costs for insured patients with financial need.

• Benefit: Helps pay copays, coinsurance, and deductibles
• Eligibility: Must have health insurance that covers Adempas; income at or below 400-500% of the Federal Poverty Level (approximately $58,000-$72,500 for an individual in 2026)
• Application: Call 866-316-7263 or visit panfoundation.org
• Note: Available to Medicare patients (unlike manufacturer copay cards)
• Caveat: Fund availability varies — the pulmonary hypertension fund may open and close throughout the year based on donations

HealthWell Foundation

Another independent nonprofit offering similar financial assistance for pulmonary hypertension patients.

• Benefit: Copay and premium assistance
• Eligibility: Income-based; check current limits on healthwellfoundation.org
• Note: Also available to Medicare patients
• Application: Online at healthwellfoundation.org or call 800-675-8416

NeedyMeds and RxAssist

These are comprehensive databases of patient assistance programs — useful for your staff to check for additional or emerging programs:

• NeedyMeds: needymeds.org — search by drug name
• RxAssist: rxassist.org — search by drug name

Generic Riociguat: Current Status

You may receive questions from patients about generic availability. Here's the current situation:

• The FDA approved a generic Riociguat (MSN Laboratories) in September 2022
• However, it is not commercially available
• Active Adempas patents don't expire until February 2034
• No generic manufacturer can legally sell Riociguat until patents expire or are successfully challenged
• For the foreseeable future, brand-name Adempas is the only option

When patients ask about generics, being transparent about this timeline — while directing them to available assistance programs — builds trust and prevents them from delaying treatment in hopes of a cheaper alternative that isn't coming soon.

Building Cost Conversations Into Your Clinical Workflow

Cost discussions shouldn't be an afterthought. Here's how to integrate them effectively:

At the Prescribing Decision

• Mention cost proactively. Don't wait for the patient to find out the price at the pharmacy. Say something like: "Adempas has a high list price, but there are excellent assistance programs. My team will help you access them."
• Initiate Aim enrollment simultaneously with prior authorization. This is the single most impactful workflow change you can make
• Document the patient's insurance type (commercial, Medicare, Medicaid, uninsured) to route them to the right program immediately

At Follow-Up Visits

• Ask about cost barriers — "Are you having any trouble affording or getting your Adempas?" Patients often won't volunteer this information
• Watch for signs of non-adherence — missed refills, dose stretching, declining exercise capacity after initial improvement
• Reassess assistance programs annually — eligibility and fund availability change; what was available last year may need to be renewed or replaced

Staff Training

• Designate a team member (nurse, MA, or patient navigator) as the Adempas access point person
• Keep the Aim phone number (855-423-3672) and PAN Foundation number (866-316-7263) accessible to all clinical staff
• Create a simple checklist: insurance type → appropriate program → enrollment initiated → follow-up date

Use Medfinder for Provider Resources

Medfinder for Providers offers tools to help your practice locate specialty pharmacies with Adempas in stock and connect patients with availability information — saving your staff time on phone calls and pharmacy coordination.

Quick Reference: Which Program for Which Patient?

• Commercially insured → Aim Co-Pay Assistance (855-423-3672) — potential $0 copay
• Medicare Part D → PAN Foundation (866-316-7263) or HealthWell Foundation (800-675-8416) — help with copays within the $2,000 annual cap
• Uninsured → Bayer US Patient Assistance Foundation via Aim (855-423-3672) — free medication
• Medicaid → Typically low or no cost-sharing; assist with prior authorization
• All patients → Enroll in Aim Patient Support Program for comprehensive access support

Final Thoughts

Adempas is a clinically essential medication — for CTEPH patients, there is no FDA-approved alternative. The science supports its use. But none of that matters if your patient can't afford to fill the prescription.

The programs available for Adempas are actually quite robust. The Aim Co-Pay Assistance Program can eliminate copays entirely for commercially insured patients. The Bayer Patient Assistance Foundation provides free medication for uninsured patients. Independent foundations like PAN and HealthWell fill the gaps for Medicare patients.

The challenge isn't that the programs don't exist — it's that patients don't know about them, or they fall through the cracks between prescription and first fill. By integrating cost conversations and program enrollment into your prescribing workflow, you can close that gap.

For more clinical information on Adempas, see our guides on side effects and monitoring, drug interactions, and helping patients find Adempas in stock. Visit Medfinder for Providers for pharmacy availability tools.